Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Easton Pharmaceuticals, Inc. (OTC: EAPH).

Full DD Report for EAPH

You must become a subscriber to view this report.


Recent News from (OTC: EAPH)

Pot stocks perk up premarket
Cannabis stocks are showing some life premarket. Cronos Group (NASDAQ: CRON ) is up  24%  on robust volume, Canopy Growth (NYSE: CGC ) is up  7%  on increased volume and Tilray (NASDAQ: TLRY ) is up  11%  on average volume. More news on: Cronos Group, Inc., Ca...
Source: SeekingAlpha
Date: September, 05 2018 07:50
Citron bearish on Tilray due to valuation; shares up 9%
Citron Research, a buyer of pot stock Tilray ( TLRY +9.4% ) up to $45, is now bearish with a fair value target of $26, calling it "by far the most expensive in the space." The stock is currently exchanging hands at $72 up over four-fold from its IPO price of $17. More news on: Tilray, In...
Source: SeekingAlpha
Date: September, 04 2018 12:19
Profit-taking pressures Tilray, down 4% premarket
Tilray (NASDAQ: TLRY ) slips  4%  premarket on light volume as investors take money off the table after the stock's ~ 160%  run-up since touching $24 on August 14. More news on: Tilray, Inc., Canopy Growth Corporation, Cronos Group, Inc., Healthcare stocks news, Consumer sto...
Source: SeekingAlpha
Date: August, 30 2018 08:09
Beverage giants eye Canadian cannabis players
The large investment by Constellation Brands ( STZ +1.1% ) in Canopy Growth Corp. ( CGC +3.8% ) is still reverberating around the beverage industry as some of the larger names scramble to keep up. More news on: Constellation Brands, Inc., Canopy Growth Corporation, Anheuser-Busch InB...
Source: SeekingAlpha
Date: August, 29 2018 10:42

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.0110.01080.0110.0102813,293
2018-12-130.01160.010410.01160.01012,794,699
2018-12-120.010.010830.01150.012,883,382
2018-12-110.011050.010310.01130.01011,525,286
2018-12-100.010740.01080.01130.0101666,209

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-14341,353813,29341.9717Short
2018-12-131,143,5832,515,19945.4669Short
2018-12-121,318,6512,783,38247.3759Short
2018-12-11604,0361,335,28645.2365Short
2018-12-10306,125666,20945.9503Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EAPH.


About Easton Pharmaceuticals, Inc. (OTC: EAPH)

Logo for Easton Pharmaceuticals, Inc. (OTC: EAPH)

Drug / OTC Research and Development

 

 

 

Current Management

  • Evan Karras / CEO, Secretary
  • Evan Karras /

Current Share Structure

  • Market Cap: $19,458,579 - 03/15/2018
  • Authorized: 3,000,000,000 - 03/15/2018
  • Issue and Outstanding: 1,151,395,236 - 03/15/2018
  • Float: 715,871,772 - 08/15/2017

 


Recent Filings from (OTC: EAPH)

Quarterly Report - Quarterly Report
Filing Type: Quarterly Report - Quarterly ReportFiling Source: OTC Markets
Filing Date: December, 07 2017

 

 


Daily Technical Chart for (OTC: EAPH)

Daily Technical Chart for (OTC: EAPH)


Stay tuned for daily updates and more on (OTC: EAPH)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: EAPH)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EAPH is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of EAPH and does not buy, sell, or trade any shares of EAPH. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/